Digestive Diseases and Sciences

, Volume 54, Issue 2, pp 389–394 | Cite as

Endocan Expression Correlated with Poor Survival in Human Hepatocellular Carcinoma

  • Geng-Wen Huang
  • Yi-Ming Tao
  • Xiang Ding
Original Article


Hepatocellular carcinoma (HCC) is the second leading cause of cancer death in China. We aimed to first present the expression of endocan in HCC tissue and its correlation with the clinicopathological features and overall survival of patients with HCC after curative hepatectomy. Immunohistochemical detection of endocan, CD34, and vascular endothelial growth factor (VEGF) were performed on samples from 100 patients with HCC. Endocan protein was expressed in endothelium of HCC tissue in all specimens, but was not expressed in endothelium of pericarcinomatous liver tissue and normal liver tissue. Microvessel density (MVD) denoted by endocan (endocan-MVD) in HCC was correlated with microscopic venous invasion and VEGF expression (< 0.05). Survival analysis showed that overall survival of patients was inversely associated with endocan-MVD (< 0.01). Multivariate analysis showed that endocan-MVD was an independent prognostic marker for overall survival of HCC (< 0.01). In conclusion, endocan-MVD was a significant factor to predict the prognosis of HCC patients after curative hepatectomy.


Endocan Immunohistochemistry Hepatocellular carcinoma Survival 



We thank Bao-An Liu and Seng-Lin Chen for evaluating the immunohistochemical results.


  1. 1.
    He J, Gu D, Wu X, Reynolds K, Duan X, Yao C et al (2005) Major causes of death among men and women in China. N Engl J Med 353:1124–1134. doi: 10.1056/NEJMsa050467 PubMedCrossRefGoogle Scholar
  2. 2.
    Fan ST, Lo CM, Liu CL, Lam CM, Yuen WK, Yeung C et al (1999) Hepatectomy for hepatocellular carcinoma: toward zero hospital death. Ann Surg 229:322–330. doi: 10.1097/00000658-199903000-00004 PubMedCrossRefGoogle Scholar
  3. 3.
    Hubert C, Sempoux C, Rahier J, Horsmans Y, Geubel A, Van Beers BE et al (2007) Prognostic risk factors of survival after resection of hepatocellular carcinoma. Hepatogastroenterology 54(78):1791–1797PubMedGoogle Scholar
  4. 4.
    Ibrahim S, Roychowdhury A, Hean TK (2007) Risk factors for intrahepatic recurrence after hepatectomy for hepatocellular carcinoma. Am J Surg 194:17–22. doi: 10.1016/j.amjsurg.2006.06.051 PubMedCrossRefGoogle Scholar
  5. 5.
    Mann CD, Neal CP, Garcea G, Manson MM, Dennison AR, Berry DP (2007) Prognostic molecular markers in hepatocellular carcinoma: a systematic review. Eur J Cancer 43:979–992. doi: 10.1016/j.ejca.2007.01.004 PubMedCrossRefGoogle Scholar
  6. 6.
    Wang SM, Ooi LL, Hui KM (2007) Identification and validation of a novel gene signature associated with the recurrence of human hepatocellular carcinoma. Clin Cancer Res 13:6275–6283. doi: 10.1158/1078-0432.CCR-06-2236 PubMedCrossRefGoogle Scholar
  7. 7.
    Poon RTP, Fan ST, Wong J (2000) Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 232:10–24. doi: 10.1097/00000658-200007000-00003 CrossRefGoogle Scholar
  8. 8.
    Wang W, Yang LY, Huang GW, Lu WQ, Yang ZL, Yang JQ et al (2004) Genomic analysis reveals RhoC as a potential marker in hepatocellular carcinoma with poor prognosis. Br J Cancer 90:2349–2355PubMedGoogle Scholar
  9. 9.
    Sun B, Zhang S, Zhang D, Du J, Guo H, Zhao X et al (2006) Vasculogenic mimicry is associated with high tumor grade, invasion and metastasis, and short survival in patients with hepatocellular carcinoma. Oncol Rep 16:693–698PubMedGoogle Scholar
  10. 10.
    Tanaka S, Arii S (2006) Current status and perspective of antiangiogenic therapy for cancer: hepatocellular carcinoma. Int J Clin Oncol 11:82–89. doi: 10.1007/s10147-006-0566-5 PubMedCrossRefGoogle Scholar
  11. 11.
    Huang GW, Yang LY, Lu WQ (2005) Expression of hypoxia-inducible factor 1 a and vascular endothelial growth factor in hepatocellular carcinoma: impact on neovascularization and survival. World J Gastroenterol 11:1705–1708PubMedGoogle Scholar
  12. 12.
    Claudio PP, Russo G, Kumar CACY et al (2004) pRb2/p130, Vascular Endothelial Growth Factor, p27(KIP1), and proliferating cell nuclear antigen expression in hepatocellular carcinoma. Clin Cancer Res 10:3509–3517. doi: 10.1158/1078-0432.CCR-03-0662 PubMedCrossRefGoogle Scholar
  13. 13.
    Ikeguchi M, Ueta T, Yamane Y, Hirooka Y, Kaibara N (2002) Inducible nitric oxide synthase and survivin messenger RNA expression in hepatocellular carcinoma. Clin Cancer Res 8:3131–3136PubMedGoogle Scholar
  14. 14.
    Poon RT, Ng IO, Lau C et al (2001) Correlation of serum basic fibroblast growth factor levels with clinicopathologic features and postoperative recurrence in hepatocellular carcinoma. Am J Surg 182:298–304. doi: 10.1016/S0002-9610(01)00708-5 PubMedCrossRefGoogle Scholar
  15. 15.
    Poon RT, Ng IO, Lau C et al (2002) Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study. J Clin Oncol 20:1775–1785. doi: 10.1200/JCO.2002.07.089 PubMedCrossRefGoogle Scholar
  16. 16.
    Wang SN, Chuang SC, Yeh YT et al (2006) Potential prognostic value of leptin receptor in hepatocellular carcinoma. J Clin Pathol 59:1267–1271. doi: 10.1136/jcp.2005.033464 PubMedCrossRefGoogle Scholar
  17. 17.
    Yang LY, Lu WQ, Huang GW, Wang W (2006) Correlation between CD105 expression and postoperative recurrence and metastasis of hepatocellular carcinoma. BMC Cancer 6:110. doi: 10.1186/1471-2407-6-110 Google Scholar
  18. 18.
    Sarrazin S, Adam E, Lyon M, Depontieu F, Motte V, Landolfi C, Lortat-Jacob H, Bechard D, Lassalle P, Delehedde M (2006) Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochem Biophys Acta 1765:25–37PubMedGoogle Scholar
  19. 19.
    van ‘t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530–536. doi: 10.1038/415530a PubMedCrossRefGoogle Scholar
  20. 20.
    Amatschek S, Koenig U, Auer H, Steinlein P, Pacher M, Gruenfelder A et al (2004) Tissue-wide expression profiling using cDNA subtraction and microarrays to identify tumor-specific genes. Cancer Res 64:844–856. doi: 10.1158/0008-5472.CAN-03-2361 PubMedCrossRefGoogle Scholar
  21. 21.
    Borczuk AC, Shah L, Pearson GD, Walter KL, Wang L, Austin JH et al (2004) Molecular signatures in biopsy specimens of lung cancer. Am J Respir Crit Care Med 170:167–174. doi: 10.1164/rccm.200401-066OC PubMedCrossRefGoogle Scholar
  22. 22.
    Grigoriu BD, Depontieu F, Scherpereel A, Gourcerol D, Devos P, Ouatas T et al (2006) Endocan expression and relationship with survival in human non-small cell lung cancer. Clin Cancer Res 12:4575–4582. doi: 10.1158/1078-0432.CCR-06-0185 PubMedCrossRefGoogle Scholar
  23. 23.
    Huang GW, Yang LY (2002) Metallothionein expression in hepatocellular carcinoma and its clinical significance. World J Gastroenterol 8:650–653PubMedGoogle Scholar
  24. 24.
    Weidner N (1995) Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 36:169–180. doi: 10.1007/BF00666038 PubMedCrossRefGoogle Scholar
  25. 25.
    El-Assal ON, Yamanoi A, Soda Y, Yamaguchi M, Iqarashi M, Yamamoto A et al (1998) Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. Hepatology 27:1554–1562. doi: 10.1002/hep. 510270613 PubMedCrossRefGoogle Scholar
  26. 26.
    McDonald DM, Foss AJE (2000) Endothelial cells of tumor vessels: abnormal but not absent. Cancer Metastasis Rev 19:109–120. doi: 10.1023/A:1026529222845 PubMedCrossRefGoogle Scholar
  27. 27.
    Abid MR, Yi X, Yano K, Shih SC, Aird WC (2006) Vascular endocan is preferentially expressed in tumor endothelium. Microvasc Res 72:136–145. doi: 10.1016/j.mvr.2006.05.010 PubMedCrossRefGoogle Scholar
  28. 28.
    Tozer GM, Kanthou C, Baguley BC (2005) Disrupting tumour blood vessels. Nat Rev Cancer 5:423–435. doi: 10.1038/nrc1628 PubMedCrossRefGoogle Scholar
  29. 29.
    Rennel E, Mellberg S, Dimberg A, Petersson L, Botling J, Ameur A et al (2007) Endocan is a VEGF-A and PI3K regulated gene with increased expression in human renal cancer. Exp Cell Res 313:1285–1294. doi: 10.1016/j.yexcr.2007.01.021 PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  1. 1.Department of General SurgeryXiangya Hospital, Central South UniversityChangshaChina

Personalised recommendations